Month: September 2026

MCLEAN, Va., Sept. 29, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII), America’s largest military shipbuilder and the global leader in autonomous seapower, was awarded a contract by the U.S. Navy to build 10 ROMULUS unmanned surface vessels (USVs) for the Medium Unmanned Surface Vessel (MUSV) program. The award marks a major advancement in the U.S. Navy’s transition from experimentation to fleet-scale deployment of trusted, operational autonomy across the maritime domain.

“HII has made deliberate, early investments in the development of autonomous systems, advancing capabilities essential to the Navy’s hedge strategy,” said Chris Kastner, HII president and CEO. “We remain firmly committed to supporting the U.S. Navy’s vision and accelerating this critical capability from production to operational deployment.”

The U.S. Navy’s selection underscores HII’s shipbuilding expertise and leadership in proven autonomous unmanned surface and underwater maritime systems to deliver reliable production at the speed and scale required for emerging unmanned fleet production and operations.

Photos accompanying this release are available at: https://www.hii.com/news/hii-wins-us-navy-contract-for-10-romulus-usvs-accelerating-deployment-of-proven-autonomous-capability.

At the core of ROMULUS is HII’s Odyssey Autonomous Control Solutions (ACS), a combat-tested autonomy suite that enables trusted, coordinated operations across surface and undersea domains. HII has delivered more than 750 REMUS unmanned underwater vehicles (UUVs) to customers in more than 30 countries. Together, ROMULUS, REMUS and Odyssey ACS provide a scalable foundation for autonomous maritime operations supporting the U.S. Navy and allied fleets.

In 2025, HII committed to securing the partners, production capacity, supplier network and infrastructure needed to move quickly from design and development to construction of ROMULUS USVs. That investment reflected HII’s continued support of the U.S. Navy’s unmanned maritime priorities and advancing the unmanned surface program with mature technology and a production-ready approach. By beginning work in 2025, HII positioned the ROMULUS program for accelerated delivery, reduced production risk and to provide the U.S. Navy with a scalable path to fielding autonomous unmanned surface capabilities at the pace the nation demands.

“Unmanned vessels ultimately must be built, integrated, tested and sustained as part of a fleet,” said Andy Green, president of HII’s Mission Technologies division. “As the nation’s largest shipbuilder, HII understands that challenge from both sides. By pairing our advanced cutting-edge technologies with our shipbuilding expertise, and leveraging experienced regional partners and suppliers, we are creating a production ecosystem capable of delivering reliable autonomous platforms at the pace and scale the U.S. Navy requires.”

Odyssey ACS: The Autonomy Behind ROMULUS

A key differentiator of ROMULUS is HII’s Odyssey ACS, a modular, open-architecture autonomy suite developed from decades of experience designing, building, operating and sustaining unmanned maritime systems.

Odyssey is designed to deliver consistent, predictable autonomous behavior, a requirement for the U.S. Navy’s transition from experimentation to operational deployment. It provides decision-making architecture that enables unmanned systems to perceive their surroundings, navigate, manage onboard systems and payloads, coordinate with other manned and unmanned platforms, and execute complex missions with limited human intervention.

Odyssey’s modular, open-architecture lets the U.S. Navy and allied partners rapidly integrate emerging sensors, command-and-control (C2) technologies and AI algorithms, ensuring ROMULUS remains upgrade-ready for evolving threat environments.

HII, with its partners Applied Intuition, Greenroom Robotics and Rodi Marine, successfully completed the evaluation phase of the MUSV program. HII’s Odyssey ACS vessel capabilities were validated through a series of operationally representative test events, demonstrating performance, reliability and mission readiness. The U.S. Navy-monitored testing took place in the Gulf of America over a 13-day period and evaluated the system under demanding, real-world operating conditions.

The most rigorous event was a long-endurance mission simulation. HII’s autonomy system successfully completed the full 420-nautical-mile mission over 28 hours, meeting all established success criteria and demonstrating the endurance and autonomous performance required for sustained maritime operations.

Designed and Built by Shipbuilders for Scale

For ROMULUS, HII is combining that expertise with a distributed production model that leverages regional shipbuilders and manufacturing partners. This approach expands available production capacity, strengthens the U.S. maritime industrial base and enables vessels to be produced efficiently and repeatedly as U.S. Navy demand grows.

HII is working with Gulf Coast build partners including Breaux Brothers Enterprises, Halimar Shipyard and Bayou Metal Supply & Manufacturing in Louisiana to support ROMULUS production, and developed in partnership with Beier Integrated Systems and Incat Crowther.

HII also recently announced a new10,000-square-foot expansion to increase the capacity of HII’s existing 40,000-square-foot unmanned manufacturing production campus capacity to build, develop and integrate advanced unmanned and autonomous maritime systems for both the REMUS family of UUVs and ROMULUS USVs.

The model allows major components and assemblies to be produced efficiently before final vessel integration, increasing throughput and creating a repeatable production architecture that can scale across the ROMULUS USV family.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

• HII on the web: https://www.HII.com/
• HII on Facebook: https://www.facebook.com/TeamHII
• HII on X: https://www.twitter.com/WeAreHII
• HII on Instagram: https://www.instagram.com/WeAreHII
• HII on LinkedIn: https://www.linkedin.com/company/wearehii

Contact:
Greg McCarthy
(202) 264-7126
gregory.j.mccarthy@hii-co.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8ad2654-8701-4404-beb0-d34b186ce8a4

Châtillon, France, September 29, 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN^® Peanut Patch in Children Aged 4-7 Years

• The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to date for this population. 
• DBV has requested Priority Review of the BLA.

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN® Peanut Patch in children with peanut allergy aged 4 through 7 years.

DBV has requested Priority Review of the BLA. The FDA previously granted Breakthrough Therapy Designation to the VIASKIN® Peanut Patch.

“The submission of our BLA brings VIASKIN® Peanut Patch, a non-invasive, practical treatment option, one step closer to being available for children ages 4 through 7 living with peanut allergy, and marks a significant milestone in DBV’s transformation into a commercial organization,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “This BLA reflects years of rigorous clinical development, meaningful contributions from the entire food allergy community, and ongoing collaboration with the FDA. We are grateful for the Agency’s constructive engagement over the last few months and look forward to working closely with them during the review process.”

The VIASKIN® Patch uses epicutaneous immunotherapy (EPIT), an innovative, non-oral, non-injection approach to food allergy treatment that delivers small amounts of an allergen protein through the skin. By using the immune properties of the skin, the VIASKIN® Peanut Patch is designed to progressively desensitize children to peanut allergy.

The BLA is supported by the positive results from the VITESSE Phase 3 clinical trial of the VIASKIN® Peanut Patch in 654 children ages 4 through 7 years with peanut allergy. VITESSE is the largest immunotherapy clinical trial to date for this population.

About the VITESSE Study
VITESSE (NCT05741476) is a global Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of the VIASKIN® Peanut patch (250 µg) in children ages 4-7 years with peanut allergy. The study enrolled 654 children randomized 2:1 to receive either VIASKIN® Peanut Patch or placebo. Conducted at 86 sites across the United States, Canada, United Kingdom, Europe, and Australia, VITESSE represents the largest immunotherapy clinical trial for this patient population. The primary endpoint is the difference between the percentage of treatment responders in the active versus placebo group after 12 months of treatment. Following the 12-month double-blind period, children were given the option to continue into an open-label extension where all participants receive VIASKIN® Peanut Patch for up to a total of three years on treatment.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® Patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, results of DBV’s clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans, timing and expectations with respect to priority review of the BLA for VIASKIN® Peanut Patch for children ages 4 through 7, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, DBV Technologies’ Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026 filed with the SEC on April 30, 2026 and July 16, 2026, respectively, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

VIASKIN is a registered trademark of DBV Technologies.

Investor Relations Contact
Virginie Boucinha
DBV Technologies
Virginie.boucinha@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com 

Attachment

• PDF Version

GRAND RAPIDS, Mich., Sept. 29, 2026 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that it expects to issue its 2026 third quarter results on Tuesday, October 27, 2026, at approximately 8:00 am ET. The release will be available on the Internet at IndependentBank.com within the “News” section of the “Investor Relations” area of the Company’s website.

Brad Kessel, President and CEO, Gavin Mohr, CFO and Joel Rahn, EVP Commercial Banking will review the quarterly results in a conference call for investors and analysts beginning at 11:00 am ET on Tuesday, October 27, 2026.

To access via phone, participants will need to register using the following link where they will be provided a phone number and access code: https://register-conf.media-server.com/register/BI8251941b98524fec94bd98aeea90727e

In order to view the webcast and presentation slides, please go to https://edge.media-server.com/mmc/p/oko972r9 during the time of the call. A replay of the webcast will be available until October 27, 2027.

About Independent Bank Corporation

Independent Bank Corporation (NASDAQ: IBCP) is a Grand Rapids, Michigan-based bank holding company and the parent company of Independent Bank and, as of July 1, 2026, Highpoint Community Bank. Independent Bank Corporation has total assets of approximately $6.3 billion and operates from 66 locations across Michigan’s Lower Peninsula. Founded in 1864 as First National Bank of Ionia, Independent Bank provides a full range of financial services, including commercial banking, consumer banking, mortgage lending, and investment services. Independent Bank expects to complete the full system integration of Highpoint Community Bank’s operations on November 9, 2026. Until conversion, customers of Highpoint Community Bank should continue using their existing Highpoint Community Bank branches, checks, bank cards, online and mobile banking, and other banking services as usual.

For more information, please visit our website at: IndependentBank.com.

Contact:	William B. Kessel, President and CEO, 616.447.3933
	Gavin A. Mohr, Chief Financial Officer, 616.447.3929

TORONTO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX: WM, OTCQB: WLBMF) (“Wallbridge” or the “Company”) held its Special Meeting of Shareholders (the “Meeting”) on September 29, 2026.

A total of 971,639,709 shares or 53.070% of the outstanding shares of the Company were represented at the Meeting. All of the matters submitted to the shareholders for approval as set out in the Company’s notice of meeting and management information circular dated August 18, 2026 (“MIC”) were approved by the requisite majority of votes cast at the Meeting.

Voting on the following matters, as described in the MIC, were as follows:

Approval of the Name Change Resolution

Votes For			Votes Against
Number	Percent		Number	Percent
958,692,422	98.667%		12,947,287	1.333%

Approval of the Share Consolidation Resolution

Votes For			Votes Against
Number	Percent		Number	Percent
955,202,010	98.308%		16,437,698	1.692%

About Wallbridge Mining

Wallbridge is focused on creating value through the exploration and sustainable development of gold projects in Quebec’s Abitibi region while respecting the environment and communities where it operates. The Company holds a contiguous mineral property position totaling 598 km2 that extends approximately 82 km along the Detour-Fenelon gold trend. The property is host to the Company’s flagship PEA stage Fenelon Gold Project, and its earlier exploration stage Martiniere Gold Project, as well as numerous greenfield gold projects.

For further information please visit the Company’s website at https://wallbridgemining.com/ or contact:

Wallbridge Mining Company Limited Brian Penny, CPA, CMA
Chief Executive Officer
Email: bpenny@wallbridgemining.com M: +1 416 716 8346

Tania Barreto, CPIR Director, Investor Relations
Email: tbarreto@wallbridgemining.com M: +1 289 819 3012